<DOC>
	<DOC>NCT01108848</DOC>
	<brief_summary>The objective of this patient registry is to collect data on the safety of Berinert速 in normal clinical practice in the United States. The patient registry will be maintained for a period of at least 3 years. The duration of individual patient participation will vary and is determined by the frequency of hereditary angioedema (HAE) attacks and the patient's need for Berinert速 treatment.</brief_summary>
	<brief_title>Patient Registry Study of Berinert速 in Normal Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<criteria>Any patient receiving CSL Behring's C1esterase inhibitor Written informed consent (may not be required for some retrospective chart review cases) Any patient participating in an HAE study using other C1inhibitors than Berinert速</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>C1-esterase Inhibitor</keyword>
	<keyword>Hereditary angioedema</keyword>
	<keyword>Acute HAE attack</keyword>
</DOC>